Back to top
more

Stryker (SYK)

(Real Time Quote from BATS)

$378.65 USD

378.65
474,383

+2.28 (0.61%)

Updated Aug 8, 2025 03:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

OPKO's BioReference Laboratories Offers COVID-19 Testing (Revised)

by Zacks Equity Research

OPKO's (OPK) BioReference Laboratories will initially provide testing for facilities at Burlington, Essex, Hudson, Ocean and Union Counties in New Jersey.

Zacks Equity Research

Here's Why Investors Should Buy Masimo (MASI) Stock Now

by Zacks Equity Research

Masimo (MASI) sees a slew of developments lately.

    Zacks Equity Research

    Masimo & University Hospitals Unite for Patient Monitoring

    by Zacks Equity Research

    Masimo (MASI) sees a plethora of developments lately.

      Zacks Equity Research

      OPKO's BioReference Laboratories Offers COVID-19 Testing

      by Zacks Equity Research

      OPKO's (OPK) BioReference Laboratories will initially provide testing for facilities at Burlington, Essex, Hudson, Ocean and Union Counties in New Jersey.

      Zacks Equity Research

      Masimo's Latest Buyout to Boost Respiratory Product Spectrum

      by Zacks Equity Research

      Masimo (MASI) expects the transaction to be neutral to 2020 earnings.

      Zacks Equity Research

      Here's Why You Should Hold Onto Baxter (BAX) Stock for Now

      by Zacks Equity Research

      Baxter (BAX) issues strong guidance for the first quarter of 2020.

      Zacks Equity Research

      Varian's (VAR) ProBeam Compact Treats First Patient at UAB

      by Zacks Equity Research

      Varian's (VAR) flagship ProBeam platform is seeing multiple developments of late.

      Zacks Equity Research

      BD (BDX) & BioGX Submit EUA to Speed Up Coronavirus Screening

      by Zacks Equity Research

      BD (BDX) expects screening to ramp up by 1,000 per day once authorized.

      Zacks Equity Research

      HealthEquity (HQY) Q4 Earnings and Revenues Top Estimates

      by Zacks Equity Research

      HealthEquity's (HQY) fiscal fourth-quarter earnings benefit from higher revenues and solid performing Service, Custodial and Interchange segments.

      Zacks Equity Research

      Baxter (BAX) Q4 Earnings Beat Estimates, Revenues In Line

      by Zacks Equity Research

      Baxter's (BAX) fourth-quarter earnings benefit from higher revenues, solid segmental performance and growth in APAC.

      Zacks Equity Research

      Here's Why You Should Hold Onto Varian Medical Stock Now

      by Zacks Equity Research

      Varian Medical (VAR) gains from solid prospects of its core Oncology Systems unit.

      Swayta Shah headshot

      5 Stocks With Solid Sales Growth to Combat Coronavirus Fears

      by Swayta Shah

      Steady sales growth is vital for making projections and strategic decisions.

      Zacks Equity Research

      Here's Why You Should Buy Cooper Companies (COO) Stock Now

      by Zacks Equity Research

      Cooper Companies (COO) lifts adjusted earnings per share view for fiscal 2020.

      Zacks Equity Research

      BD MAX Gets CE Mark for Coronavirus Detection, Shares Up

      by Zacks Equity Research

      BD (BDX) and Spain's CerTest Biotec collaborate to detect the COVID-19 in Europe.

      Sreoshi Bera headshot

      Robotics & AI Make Inroads in HealthCare: Stocks to Benefit

      by Sreoshi Bera

      Robotics and AI make rapid advancement in the field of healthcare. Here are five stocks that you can bet on.

      Zacks Equity Research

      Allscripts' Veradigm Business Line Unveils New Solution

      by Zacks Equity Research

      Allscripts' (MDRX) Veradigm business line introduces new solution that will drive growing medication adherence and improve patient care.

      Zacks Equity Research

      Cooper Companies (COO) Misses on Q1 Earnings, Lifts View

      by Zacks Equity Research

      Cooper Companies (COO) gains from core CVI segment in fiscal Q1.

      Zacks Equity Research

      Allscripts (MDRX) Q4 Earnings and Revenues Miss Estimates

      by Zacks Equity Research

      Allscripts (MDRX) fourth-quarter results gain from higher revenues along with growth in bookings. Contraction in both gross and operating margins remains a woe.

      Zacks Equity Research

      National Vision (EYE) Rides on Robust Growth Across All Lines

      by Zacks Equity Research

      National Vision (EYE) continues to register strong segmental performances.

      Zacks Equity Research

      Veeva Systems (VEEV) Q4 Earnings and Revenues Beat Estimates

      by Zacks Equity Research

      Veeva Systems (VEEV) gains from segmental strength in the fiscal fourth quarter.

      Zacks Equity Research

      Here's Why You Should Hold Avanos Medical (AVNS) Stock Now

      by Zacks Equity Research

      Avanos (AVNS) gains from solid fourth-quarter show despite headwinds in the Acute Pain business.

      Zacks Equity Research

      What's in Store for Cooper Companies (COO) Q1 Earnings?

      by Zacks Equity Research

      Cooper Companies (COO) fiscal first-quarter performance is likely to reflect better-than-expected performance at CVI and CSI, and higher revenues.

      Zacks Equity Research

      DENTSPLY SIRONA (XRAY) Q4 Earnings Lag Estimates, Sales Rise

      by Zacks Equity Research

      DENTSPLY SIRONA (XRAY) gains from the Technologies & Equipment arm in Q4.

      Zacks Equity Research

      Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates

      by Zacks Equity Research

      Glaukos (GKOS) fourth-quarter results benefit from revenue growth. However, rise in operating expenses remains a concern.

      Trina Mukherjee headshot

      Medical Products Industry Outlook: Growth Prospects Bright

      by Trina Mukherjee

      Growth prospects look bright for the Zacks Medical Products industry, courtesy of AI, Medical Mechatronics and Robotics and growing R&D expenditure.